MedTrace Logo

Lutonix® DCB for Treatment of Long Lesions in Femoropopliteal Arteries

NCT02013271 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 125

Last updated 2019-10-08

No results posted yet for this study

Summary

To demonstrate efficacy and safety of the Lutonix® Drug Coated Balloon for treatment of long TASC II Class C and D lesions (≥ 14 cm) lesions in the SFA

Conditions

  • Femoral Artery Occlusion
  • Femoral Arterial Stenosis

Interventions

DEVICE

Lutonix Paclitaxel Drug Coated Balloon (DCB)

Patients exposed to the DCB as part of their routine care.

Sponsors & Collaborators

  • C. R. Bard

    lead INDUSTRY

Principal Investigators

  • Martin Banyai, MD, PhD · Cantonal Hospital, Lucerne

  • Prof. Eric Ducasse, MD, PhD · University Hospital, Bordeaux

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2016-05-23
Completion
2018-06-13

Countries

  • Austria
  • Belgium
  • France
  • Germany
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02013271 on ClinicalTrials.gov